Skip to Main Content

As Purdue Pharma faced serious challenges to OxyContin sales, the company was advised to consider paying rebates of up to $14,000 to health insurers for each patient who was harmed by its opioid painkiller in order to maintain those crucial business relationships, according to court documents.

The suggestion was contained in a proposal made three years ago by McKinsey consultants as the drug maker faced a fast growing number of lawsuits from state and local governments, federal guidelines about limiting opioid prescribing, and restrictions placed by some health insurers on formularies, the lists of medicines eligible for coverage.


In response, the company was presented with different options to “rapidly address market access challenges,” according to a slide presentation made to Purdue board members that was contained in court documents (look here and scroll down). And one of those options involved offering rebates to health insurers and pharmacy benefits managers as a way to maintain formulary status for the opioid painkillers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.